ArticleFrontiers in oncology2022

Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer.

David Howard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.